We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
- Authors
Morio, Kayoko; Watanabe, Jun; Tsujimoto, Yasushi
- Abstract
To the editor: We read the prospective, open-label, randomized trial reported by Patel et al. [[1]] with great interest and appreciate their effort in clarifying the chemotherapy-induced nausea-vomiting (CINV) efficacy of aprepitant plus ondansetron in patients receiving adjuvant temozolomide. Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
- Subjects
ONDANSETRON; TEMOZOLOMIDE; EMPLOYMENT references; RANDOMIZED controlled trials; PROGNOSIS
- Publication
Supportive Care in Cancer, 2020, Vol 28, Issue 12, p5589
- ISSN
0941-4355
- Publication type
Letter
- DOI
10.1007/s00520-020-05537-3